A Robust Market: Rich with Opportunities with Increasing Demand for Novel Treatment and Expected to Reach USD 7.06 Billion in 2028

New Tissue Nanotransfection Technology (TNT) to Bring Revolution?

According to the latest study, tissue engineering will increase in demand and result in better growth. Nanotransfection is a non-invasive, Nano-chip device that uses a technology called tissue nano transfection (TNT) that has been developed to reprogram one type of tissue into another with skin for fraction of a second by simple touch and electric spark. The nano transfection technology (TNT) has two most important mechanisms as follows,

• Delivery of cargo to adult cells in the live body is the main purpose of designing the nanotechnology-based chip hardware.
• Another important purpose of TNT technology is, the design of specific biological cargo for cell conversion allows such cargo, to convert an adult cell from one type to another of interest.

The TNT technology is capable of, delivering cargo to skin cells such that skin cells become vasculogenic cells with tropical contact of the Nano-chip hardware with the skin for fraction of a second. This technology can be used for the treatment of wounds of injured soldiers, reducing diabetic complications, healing burns, and re-growing damaged and diseased tissue.

Increasing skin diseases, the prevalence of chronic diseases & trauma emergencies, and increasing consciousness regarding related to tissue engineering, along with potential pipeline products are some of the major factors responsible for the growth of tissue nano transfection technology. Furthermore, increasing investment by several governments and various private organizations in research and development activities is likely to boost the market growth.

Developed nations have adopted technological advancements in regenerative medicine sectors further helping the expansion of the market. Also, as there is no need for laboratory-based procedures for tissue nano transfection along with the non-invasive ability and may be implemented at the point of care is increasing the adoption of this technology is further expanding the market. However, strict government regulations and the high cost of treatment may act as a restraining factor and hamper the growth of the market.

What will be the market by 2028?

Our report on the tissue nano transfection market has covered the study of the latest development and investment in the market. The market drivers, restraints, and opportunities along with COVID-19 impact analysis, historical & descriptive analysis, forecasts & predictive analysis, value chain analysis, regulatory analysis, market attractiveness analysis, key segment analysis by country, competitive landscape and company market shares, and porter’s five forces analysis have been delivered for the forecast period, which drives from 2021 to 2028 with 2020 as the base year. The global tissue nano transfection market is valued at USD 2.07 billion in 2020 and is expected to reach USD 7.06 billion in 2028 and is anticipated to grow at a compound annual growth rate (CAGR) of 16.6% over the forecast period of 2021-2028.

In the year 2020, around 39,000 surgeries were carried out only in the U.S. Very nearly 9-11 million Americans suffer from wounds. Thus as being non-invasive and can be implemented at the point of care procedure, the demand for TNT technology is surging in turn thriving the growth of the market.

Some of the key players in the tissue nano transfection market include Osiris Therapeutics (U.S.), Zimmer Biomet (U.S.), AbbVie Inc. (Allergan) (U.S.), Integra Lifesciences (U.S.), Bio Tissue Technologies (Florida), B. Braun Melsungen AG (Germany), Becton, Dickinson, and Company (C. R. Bard) (U.S.), Organogenesis (U.S.), Biotime Inc. (U.S.), among others.

North America is estimated to dominate the tissue nano transfection market. High healthcare spending, availability of private and government funding, advanced technology for diagnosis and treatment of chronic disorders is estimated to witness market growth in the near future. Also, the presence of a large pool of the geriatric population in the region is anticipated to propel the tissue nano transfection market growth in the near future over the forecast period.

Asia Pacific is estimated to grow at the fastest CAGR of 19% over the forecast period of 2021-2028.